Over 70 international experts from academia, industry and biotech will address issues to learn about the latest trends and explore hands-on approaches to tech transfer and open innovation in the field of Life Sciences, by sharing their experience and knowledge.

The last confirmed speakers are:

  • Ward Capoen, Senior Analyst, V-Bio Ventures [BE]
  • Barbara Domayne-Hayman, CBO, Puridify [UK]
  • Douglas Dundonald, Founder and Director, Anglo Scientific [UK]
  • Hakan Goker, Senior Investment Director, Merck Ventures [NL]
  • Frank Hensel, Senior Investment Manager, High-Tech Gründerfonds [DE]
  • Paul Hermant, Corporate & Finance Partner, Bird & Bird [BE]
  • Klaus Mendla, Business Development and Licensing, Boehringer Ingelheim [DE]
  • Miguel Mulet, Director Strategy and New Projects, TiGenix [BE]
  • Pascal Neuville, CEO, Domain Therapeutics [FR]
  • Michael Nowak, Owner, Nowak Ventures [US]
  • Gérard-Marie Papierok, Honorary Chairman of Eurobiomed Competitive Cluster Public Research and Clusters Partnership Manager, Virbac [FR]
  • James Peyer, Managing Partner, Apollo Ventures [US]
  • Tamar Raz, CEO, Hadasit Medical Research Services & Development [IL]
  • Christian Tidona, Director and Founder, BioMed X [DE]
  • Wendy White, Senior VP, Dohmen Life Science Services [US]

EVOTEC CEO,  Dr. Werner Lanthaler will be speaking at the Plenary Session of BioFIT 2014, on December 2nd at 11am:

Accessing innovation: how to build long term partnerships?

Pharma’s interest on early stage is no longer news in the life sciences industry. In their quest to accessing knowledge, pharma and large biotech got more and more involved in early stage research, either by supporting big consortia or building collaborative research partnerships directly with academia. However, what do we know about the success of such partnerships and big consortia? Have they really worked and what were the outcomes? Where are we today in terms of long-term collaborations? Let’s hear from real experiences, what worked and what didn’t, what lessons have been learned and how have these helped in forging true partnerships.

  • Adrian CARTER, Vice President of Global Research Networking, Boehringer Ingelheim (DE)
  • Wen Hwa LEE, Strategic Alliances Manager, University of Oxford, Nuffield Department of Medicine (UK)
  • Manfred HORST, Director, Scientific Liaison France, Ge, Eastern EU Licensing & External Research EU, Merck Sharp & Dohme (FR)

Dr. Werner Lanthaler’s Biography
Dr Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company’s major corporate milestones including the product approval of Intercell’s Japanese Encephalitis Vaccine, the company’s acquisitions and strategic pharma partnerships, as well as the company’s Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company.

He holds a doctorate in economics from Vienna University, earned his Master’s degrees from Harvard University, and holds a degree in Psychology.

See full program

BioFIT 2014 speakers list

Pascale REDIG, Sr Category  Manager Research & Academic Partnerships at Janssen Research & Development Procurement, JANSSEN PHARMACEUTICA will share the panel session on creative solutions to difficult problems in dealmaking.

Emerge and happen: creative solutions to difficult problems in dealmaking, on December 3rd at 11am

That things can go wrong in negotiations and partnership is not surprising. However, when you encounter these problems, sometimes creative solutions are needed in order to finally create a mutually beneficial partnership. During this interactive session, the panelists will discuss the common and no so common pitfalls in partnering and negotiations, as well as share their experience on the different stages of negotiations, the difficulties they ran into and the solutions they found.

Together with Stefan LENSKY, VP Strategic Transaction & Alliances, BOEHRINGER INGELHEIM  and Juergen WALKENHORST, Head of Life Sciences, PROVENDIS GmbH, they will discuss and answer the audience’s questions on dealmaking.

DON’T MISS the connected session giving you the key tools to best apply your strategic alliance management.

Make it work and last: how to best apply strategic alliance managemen on December 3rd at 2pm

The deal signature is just the beginning of a long road to travel for putting in place a successful partnership. The alliance management is an important piece of the puzzle and if well implemented and understood by both parties, it becomes an effective and invaluable tool in the management of the deal. Let’s discuss how to set it correctly on paper and how to identify the right key licensing terms to the deal and how to manage the partnership in an efficient and rewarding way for both parties.

Apply to share this panel with our experts

See full conference program

Check full list of  speakers

Bernd STOWASSER, Head of European Public Private Partnerships at SANOFI Germany will join BioFIT as a speaker and discuss latest issues on Big consortia: how they work and what are their outcomes.

Many companies and research institutes are getting more and more involved in consortia of different sizes in order to work together around specific questions they are all looking to find an answer to. Of course their organization can be very different depending on the number of partners involved and the questions addressed. But how can their outcomes be evaluated, knowing that what comes out is non-tangible knowledge which itself is later used in other R&D processes in order to obtain real results? Moreover, what type of guidance is necessary in order make them work and obtain successful outcomes?

Come learn more and discuss with our speakers on December 2nd at 9am.

Moderator: Hugh LAVERTY, Senior Scientific Project Manager, IMI – Innovative Medicines Initiative (BE)


  • Bernd STOWASSER, Head of Public Private Partnerships – External Innovation & Science Policy, Sanofi (DE)
  • Nicolas CARBONI, President, SATT Conectus Alsace (FR)
  • Jacky VONDERSCHER, President, Enyo Pharma (FR)
  • Bruno FRANCOIS, Clinical Lead COMBACTE Consortium, CHU Limoges/Inserm (FR)

Check full agenda

Check speakers